Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study

2022182 citationsJournal Articlebronze Open Access

Authors

Good health and well-being

Published in: Cell Research

Volume 32, Issue 11, pp. 995-1007

Field-Weighted Citation Impact: 17.37